Chair of Pediatrics, Department of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
Arch Med Sci. 2012 Dec 20;8(6):1076-82. doi: 10.5114/aoms.2012.32419. Epub 2012 Dec 19.
Venom allergy, though rare, may seriously influence health-related quality of life (HRQoL). There is a paucity of research on HRQoL of adolescents and young adults with Hymenoptera venom allergy. The aim was to assess the level of HRQoL and to evaluate its independent predictors in Polish adolescents and young adults treated with venom immunotherapy.
A multicenter cross-sectional study based on the Vespid Allergy Quality of Life Questionnaire (VQLQ) adapted for Polish adolescents was used. The study sample included 87 patients (14-21 years) studied at different stages of venom immunotherapy (VIT). Statistical analysis was done with multivariate linear regression.
Anxiety level was higher in patients with 4(th) grade of Mueller's classification (anaphylactic shock) than in those with 3(rd) grade (B = 0.84, 95% CI = 0.07-1.61, p = 0.03). Caution increased along with an increase of anxiety of adolescents treated with VIT (B = 0.54, 95% CI = 0.39-0.68, p < 0.01). Level of limitations increased with increasing caution of adolescents (B = 0.63, 95% CI = 0.35-0.91, p < 0.01). Discomfort increased along with a rise of caution of patients (B = 0.38, 95% CI = 0.22-0.55, p < 0.01). Similarly, it increased with an increase of their feeling of limitations (B = 0.37, 95% CI = 0.23-0.51, p < 0.01). The level of discomfort in adolescents treated with VIT was lower in those who were treated with conventional protocol in comparison to those treated with rush or ultra-rush ones (B = -0.47, 95% CI = -0.90 - -0.03, p = 0.04).
Severity of anaphylactic reaction is an independent determinant of anxiety level in adolescents treated with VIT. The VIT protocol affects HRQoL of treated patients.
毒液过敏虽然罕见，但可能严重影响健康相关生活质量（HRQoL）。目前关于膜翅目毒液过敏青少年和年轻人 HRQoL 的研究较少。本研究旨在评估波兰接受毒液免疫治疗的青少年和年轻人的 HRQoL 水平，并评估其独立预测因素。
采用基于波兰青少年适应性膜翅目过敏生活质量问卷（Vespid Allergy Quality of Life Questionnaire，VQLQ）的多中心横断面研究。研究样本包括 87 名不同毒液免疫治疗阶段的患者（14-21 岁）。采用多元线性回归进行统计分析。
Mueller 分级（过敏反应性休克）第 4 级患者的焦虑水平高于第 3 级（B = 0.84，95%CI = 0.07-1.61，p = 0.03）。接受 VIT 治疗的青少年焦虑程度越高，谨慎程度越高（B = 0.54，95%CI = 0.39-0.68，p < 0.01）。青少年谨慎程度越高，活动受限程度越高（B = 0.63，95%CI = 0.35-0.91，p < 0.01）。随着患者谨慎程度的增加，不适感增加（B = 0.38，95%CI = 0.22-0.55，p < 0.01）。同样，随着他们的受限感增加，不适感也增加（B = 0.37，95%CI = 0.23-0.51，p < 0.01）。与常规方案相比，接受 rush 或 ultra-rush 方案治疗的青少年接受 VIT 治疗的不适感水平较低（B = -0.47，95%CI = -0.90 - -0.03，p = 0.04）。
接受 VIT 治疗的青少年中，过敏反应严重程度是焦虑水平的独立决定因素。VIT 方案会影响接受治疗患者的 HRQoL。
